Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Drug firm conflicting interests. If only WHI was done well.

Stevenson JC, Hodis HN, Pickar JH, Lobo RA.

BMJ. 2010 Feb 16;340:c591. doi: 10.1136/bmj.c591. No abstract available. Erratum in: BMJ. 2010;340:c1135.

PMID:
20160317
2.

Drug firm conflicting interests. If only industry funded trials were as well done as the WHI.

Barrington KJ.

BMJ. 2009 Dec 31;339:b5655. doi: 10.1136/bmj.b5655. No abstract available.

PMID:
20044404
3.

WHI findings another blow to hormone replacement therapy.

Traynor K.

Am J Health Syst Pharm. 2003 Jul 15;60(14):1409-10. No abstract available.

PMID:
12892024
4.

Women's health. U.K. hormone trial to pause for review.

Enserink M.

Science. 2002 Aug 2;297(5582):755-7. No abstract available.

PMID:
12161626
5.

Drug firm conflicting interests. Radical change, not tweaking, is needed.

Noble JH Jr.

BMJ. 2009 Dec 31;339:b5656. doi: 10.1136/bmj.b5656. No abstract available.

PMID:
20044405
6.

Drug firm conflicting interests. Quis custodiet ipsos custodes?

Whitmarsh JR.

BMJ. 2009 Dec 31;339:b5657. doi: 10.1136/bmj.b5657. No abstract available.

PMID:
20044406
7.

HRT: what to do now.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2002 Oct;14(8):1-2, 7. No abstract available.

PMID:
12425274
8.

Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? No.

Lawton V.

BMJ. 2009 Nov 27;339:b4953. doi: 10.1136/bmj.b4953. No abstract available.

PMID:
19946144
9.

Why individualizing hormone therapy is crucial: putting the results of the WHI trial into perspective.

Notelovitz M; Women's Health Initiative.

Medscape Womens Health. 2002 Jul-Aug;7(4):9. No abstract available.

10.

Hormone replacement therapy aggravates postmenopausal urinary incontinence.

[No authors listed]

Prescrire Int. 2006 Aug;15(84):137-8.

PMID:
16989027
11.

Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives.

Krieger N, Löwy I, Aronowitz R, Bigby J, Dickersin K, Garner E, Gaudillière JP, Hinestrosa C, Hubbard R, Johnson PA, Missmer SA, Norsigian J, Pearson C, Rosenberg CE, Rosenberg L, Rosenkrantz BG, Seaman B, Sonnenschein C, Soto AM, Thornton J, Weisz G.

J Epidemiol Community Health. 2005 Sep;59(9):740-8. Review.

12.

Seeding trials: just say "no".

Sox HC, Rennie D.

Ann Intern Med. 2008 Aug 19;149(4):279-80. No abstract available. Erratum in: Ann Intern Med. 2008 Sep 16;149(6):439.

PMID:
18711161
13.

Clinical trials in Canada: whose interests are paramount?

Lexchin J.

Int J Health Serv. 2008;38(3):525-42.

PMID:
18724580
14.

Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative.

Kuller LH; Women's Health Initiative.

Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):11-6. Review.

15.
16.

Investigator-initiated trials are more impartial.

Johnston BC, Vohra S.

Nature. 2006 Sep 14;443(7108):144. No abstract available.

PMID:
16971926
17.

ADVANTAGE: Merck does say "no".

Rabin A.

Ann Intern Med. 2008 Nov 18;149(10):774. No abstract available.

PMID:
19017608
18.

ADVANTAGE: Merck does say "no".

Edelman JM.

Ann Intern Med. 2008 Nov 18;149(10):774-5; author reply 775. No abstract available.

PMID:
19017607
19.

ADVANTAGE: science first, marketing second.

Edelman JM.

Ann Intern Med. 2008 Nov 18;149(10):773; author reply 773-4. No abstract available.

PMID:
19017606
20.

Unravelling industry bias in clinical trials.

Gluud LL.

Pain. 2006 Apr;121(3):175-6. Epub 2006 Mar 2. No abstract available.

PMID:
16513277
Items per page

Supplemental Content

Write to the Help Desk